Robert Terkeltaub, M.D. is Professor Emeritus of Medicine at the University of California, San Diego. After earning his medical degree from McGill University in Montreal, Canada, Dr. Terkeltaub completed postdoctoral research training in Immunopathology at The Scripps Research Institute in La Jolla, CA. His research concentrates on gout and other forms of crystal deposition disease, gout clinical trial and treatment guidelines and outcomes in the disease, as well as the interfaces of inflammation, uric acid metabolism, and skeletal biology in these disorders. Among his achievements, Dr. Terkeltaub has authored or coauthored approximately 210 original, peer-reviewed journal articles and over 120 invited articles and book chapters, and 2 textbooks on gout and crystal deposition diseases. His research has been funded for decades by the NIH, VA, and Industry, and has been cited over 25,000 times, with an H-index of 92. He was the sixth Morris Ziff Distinguished Lecturer in Rheumatology at UT Southwestern Medical Center in Dallas, and first Malawista Memorial Lecturer at the ACR, and was awarded Honorary Professor at Qingdao University School of Medicine in China. Dr. Terkeltaub was co-Editor for 8 years, and first ever Review Articles Editor of Arthritis and Rheumatology, regularly serves on multiple editorial boards and scientific advisory committees. He is founding President of the 300 member strong global research networking and mentoring organization G-CAN (Gout, Hyperuricemia and Crystal-Associated Disease Network). In 2022, he also founded the first journal specifically for gout and crystal deposition disease (GUCDD (gout, urate, and crystal deposition disease)